NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On September 28, 2025, MoonLake disclosed the 1 ...

NEW YORK--(BUSINESS WIRE)---- $MRX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc ("Marex†or the "Company†) (NASDAQ: MRX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On August 5, 2025, NINGI Research released a report accusi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Cytokinetics, Inc. following a significant stock drop after the FDA extended the review period for its heart drug aficamten due to the company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) with its New Drug Application (NDA) [3][2]. Company Summary - Cytokinetics, Inc. (NASDAQ: CYTK) experienced a stock decline of $5.57, or 12.9%, closing at $37.35 per share on May 2, 2025, after the FDA's announcement regarding the extended review period for aficamten [3]. - The company admitted to initially filing its NDA without a REMS, despite prior discussions with the FDA about safety and risk mitigation [3]. Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. - The firm is encouraging investors who suffered losses in Cytokinetics to contact them to discuss their legal options [1][4].

Core Insights - Faruqi & Faruqi, LLP is investigating potential securities law violations at Lantheus Holdings, Inc. following disappointing financial results and significant stock price decline [2][3][4] Financial Performance - Lantheus reported first-quarter results on May 7, 2025, that fell below market expectations, particularly with Pylarify's performance [3] - On August 6, 2025, Lantheus announced further disappointing results, reducing growth expectations for Pylarify by 8.3% year-over-year and slashing fiscal year 2025 growth projections [3] Stock Market Reaction - Following the August 6 announcement, Lantheus' stock price dropped 28.8% in one day, from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025 [4]

Core Insights - Faruqi & Faruqi, LLP is investigating potential securities law violations at Quanex Building Products Corporation following significant financial losses reported by the company [2][3][4] Financial Performance - Quanex reported a diluted EPS of ($6.04) for Q3 FY2025, a substantial decline from $0.77 in the same period last year [3] - The company disclosed operational issues at its Tyman Mexico hardware business, which negatively impacted EBITDA by nearly $5 million in Q3 [4] - Adjusted EBITDA for the quarter was reported at $70.30 million, with the company adjusting for lower expected volumes and delaying procurement savings from Tyman integration [3][4] Stock Market Reaction - Following the earnings announcement, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025, with unusually high trading volume [4] - The stock continued to decline on September 8, 2025, dropping an additional $1.98, or 10.9%, to close at $16.20 per share [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Jasper Therapeutics, Inc. following significant issues related to its drug studies and a substantial stock price drop [2][5]. Group 1: Company Issues - Jasper Therapeutics announced on July 7, 2025, that data from its BEACON Study was compromised due to problems with a specific drug product lot, affecting 10 out of 13 patients [3]. - The same defective lot was also used in the ETESIAN Study, leading to the halt of that study and a pause in asthma development [4]. - The company is implementing cost-cutting measures and potential restructuring to extend its cash runway, contradicting previous assurances of financial stability through Q3 2025 [4]. Group 2: Stock Performance - Following the announcement of the compromised data and halted studies, Jasper's stock price fell by $3.73, or 55.1%, closing at $3.04 per share on July 7, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at aTyr Pharma, Inc. following the company's announcement of disappointing clinical trial results that led to a significant drop in stock price [2][4]. Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker ATYR [2]. - The company recently reported that its EFZO-FIT study did not meet its primary endpoint, which was the change from baseline in mean daily oral corticosteroid dose at week 48 [3]. Market Reaction - Following the announcement of the failed study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share by the close of trading on September 15, 2025, representing a decline of approximately 83.2% in a single day [4].

Synopsys's stock price fell $216.59, or 35.8%, to close at $387.78 per share on September 10, 2025, thereby injuring investors. SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Synopsys Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options If you suffered losses in Synopsysand would like to discuss your legal rights, call Faruqi & Faruqi ...

Share Nov 6, 2025 11:07 AM Eastern Standard Time SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered losses in Tvardiand would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also cl ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at KBR, Inc. following a significant drop in its stock price after the announcement of the termination of a contract by HomeSafe Alliance [2][3]. Group 1: Investigation Details - The investigation is being led by Faruqi & Faruqi, a national securities law firm known for recovering hundreds of millions of dollars for investors since its establishment in 1995 [2]. - Investors who suffered losses in KBR are encouraged to contact the firm to discuss their legal options [1][4]. Group 2: Stock Price Impact - On June 20, 2025, KBR's stock price fell by $3.85 per share, a decrease of 7.29%, closing at $48.93 following the contract termination announcement [3]. - The decline continued on June 23, 2025, with an additional drop of $1.30 per share (2.65%), closing at $47.63 [3].